NCT02243605View on ClinicalTrials.gov

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 19, 2014

Primary Completion Date

June 30, 2019

Study Completion Date

July 11, 2026

Conditions
Metastatic Ewing SarcomaMetastatic OsteosarcomaRecurrent Ewing SarcomaRecurrent OsteosarcomaStage III Osteosarcoma AJCC v7Stage IV Osteosarcoma AJCC v7Stage IVA Osteosarcoma AJCC v7Stage IVB Osteosarcoma AJCC v7Unresectable Ewing SarcomaUnresectable Osteosarcoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (11)

13385

Hopital De La Timone, Marseille

21079

Centre Georges-Francois Leclerc, Dijon

31052

Center Claudius Regaud, Toulouse

33076

Institut Bergonie Cancer Center, Bordeaux

44805

Institut de Cancerologie de l'Ouest-Rene Gauducheau, Saint-Herblain

59020

Centre Oscar Lambert, Lille

67091

CHRU Strasbourg - Hospital Civil, Strasbourg

69373

Centre Leon Berard, Lyon

75005

Institut Curie Paris, Paris

94805

Gustave Roussy, Villejuif

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH